BioSpace News Archive

- Tuesday, June 1 st – 3:30 p.m. ET - Nuvo Pharmaceuticals ® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, has been invited to present at the Summer Solstice

Deal allows global cardiac device manufacturer to enhance its offerings in the U.S. with Implicity’s cloud-based and AI-driven universal cardiac remote monitoring platform to provide high-value services to healthcare providers

Research includes innovations in lipid nanoparticle technology for mRNA delivery into hematopoietic stem and progenitor cells Intracellular event-guided rational design of lipid nanoparticle Assessment and prediction of SARS-CoV-2 variants for selection of COVID-19 booster vaccines

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET.

MIMEDX Group, Inc. announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 2:00 PM Eastern Time.

Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 8:00am Eastern Time.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, hosted a virtual Clinical Day on May 20, 2021 to provide an update on the clinical progress of ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (wet AMD)

Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today that John Murphy, Ph.D., has joined as Chief Scientific Officer and Greg Hoffman, Ph.D., has joined as Vice President, Discovery & Platform

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced its participation in the following conferences in June.